◎ Sugi Atlas

Atlas / Drug / Ascorbic Acid

Ascorbic Acid

drug
On this page

Also known as Acide ascorbiqueAcido ascorbicoAcidum ascorbicumAscoltinAscorAscorbateAscorbic acid (vit c)Ascorbic acid component of moviprepAscorbic acid component of plenvuAscorbic acid component of vitapedl-AscorbicapAscorbicum acidumAscurBassett'sE-300E300FEMA NO. 2109Haliborange

Summary

Ascorbic Acid (CHEMBL196) is an approved small-molecule flour treatment agent (ATC G01AD03) targeting SLC23A1 and SLC23A2; indicated across 104 conditions including iron deficiency anemia and pneumonia.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: G01AD03 (+2 more)
  • Targets: 2 (SLC23A1, SLC23A2)
  • Indications: 104 conditions
  • Clinical trials: 399
  • Chemistry: C6H8O6

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL196
NameAscorbic Acid
TypeSmall molecule
Max phase4
ChEBICHEBI:29073
ATCG01AD03, A11GA01, S01XA15
Molecular formulaC6H8O6
InChIKeyCIWBSHSKHKDKBQ-JLAZNSOCSA-N

SMILES: [H][C@]1([C@@H](O)CO)OC(=O)C(O)=C1O

ChEBI definition: The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.

Pharmacological roles (ChEBI): coenzyme, flour treatment agent, cofactor, skin lightening agent, geroprotector.

Other ChEBI roles (chemical / environmental): food antioxidant, plant metabolite, food colour retention agent.

Also known as: Acide ascorbique, Acido ascorbico, Acidum ascorbicum, Ascoltin, Ascor, Ascorbate, Ascorbic acid, Ascorbic acid (vit c), Ascorbic acid component of moviprep, Ascorbic acid component of plenvu, Ascorbic acid component of vitaped, l-

Parent form; salt/anhydrous children: CHEMBL3350399

Patent coverage: 419,869 distinct patent families (1,033,030 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
SLC23A1Sodium-dependent vitamin C transporter 1Binding0%Q9UHI7
SLC23A2Sodium-dependent vitamin C transporter 20%Q9UGH3

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Alpha-2B adrenergic receptor, Tyrosinase, Prostaglandin G/H synthase 1, Pancreatic alpha-amylase, Urease.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ADRA2B9.3EC500.5nMCHEMBL_ACT_2408159
PTGS16.27AC50533.2nMCHEMBL_ACT_25205609
PTGS16.21AC50616.4nMCHEMBL_ACT_25206539
P073745.07IC508590nMCHEMBL_ACT_24815645

Target pathways

Aggregated over 2 target gene(s): SLC23A1, SLC23A2.

Top Reactome pathways

4 total, by targets touching each:

PathwayTargetsGenes
Metabolism2SLC23A1, SLC23A2
Vitamin C (ascorbate) metabolism2SLC23A1, SLC23A2
Metabolism of water-soluble vitamins and cofactors2SLC23A1, SLC23A2
Metabolism of vitamins and cofactors2SLC23A1, SLC23A2

Dominant GO biological processes

GO termTargets
sodium ion transport2
L-ascorbic acid transmembrane transport2
L-ascorbic acid metabolic process2
monoatomic ion transport2
transmembrane transport2
brain development1
response to toxic substance1
nucleobase transport1
lung development1
dehydroascorbic acid transport1
urate transport1
sodium ion transmembrane transport1
response to oxidative stress1
cell adhesion1
blood circulation1

Indications & clinical

Indications

104 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
iron deficiency anemia4MONDO:0001356HP:0001891
pneumonia4MONDO:0005249EFO:0003106
anemia4MONDO:0002280EFO:0004272
chronic kidney disease4MONDO:0005300EFO:0003884
eye disorder4MONDO:0005328EFO:0003966
scurvy4MONDO:0009412EFO:1001169
diabetes mellitus3MONDO:0005015EFO:0000400
colorectal adenocarcinoma3MONDO:0005008EFO:0000365
atrial fibrillation3MONDO:0004981EFO:0000275
uterine corpus leiomyoma3MONDO:0007886EFO:0000731
heart failure3MONDO:0005252EFO:0003144
atrial flutter3MONDO:0005310EFO:0003911
colorectal neoplasm3MONDO:0005335EFO:0004142
toxic shock syndrome3MONDO:0001881EFO:0006834
myocardial ischemia3MONDO:0024644EFO:1001375
macular degeneration3MONDO:0003004EFO:0009606
complex regional pain syndrome3MONDO:0019369EFO:1001998
gastric neoplasm3MONDO:0021085MONDO:0001056
severe acute respiratory syndrome3MONDO:0005091EFO:0000694
respiratory tract infectious disorder3MONDO:0024355MONDO:0024355
influenza3MONDO:0005812EFO:0007328
cataract3MONDO:0005129MONDO:0005129
coronary artery disorder3MONDO:0005010EFO:0001645
paraganglioma3MONDO:0000448EFO:1000453
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
injury2MONDO:0021178EFO:0000546
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
prostate adenocarcinoma2MONDO:0005082EFO:0000673
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
metastatic prostate carcinoma2MONDO:0004956EFO:0000196
myelodysplastic syndrome2MONDO:0018881EFO:0000198
acute myeloid leukemia2MONDO:0018874EFO:0000222
clear cell renal carcinoma2MONDO:0005005EFO:0000349
epilepsy2MONDO:0005027EFO:0000474
glioblastoma2MONDO:0018177EFO:0000519
preeclampsia2MONDO:0005081EFO:0000668
plasma cell myeloma2MONDO:0009693EFO:0001378
muscle tissue disorder2MONDO:0003939EFO:0002970
nicotine dependence2MONDO:0008575EFO:0003768
pancreatic neoplasm2MONDO:0021040EFO:0003860
stomatitis2MONDO:0004842EFO:1001904
Hodgkins lymphoma2MONDO:0004952EFO:0000183
myocardial infarction2MONDO:0005068EFO:0000612
urinary tract infection2MONDO:0100338EFO:0003103
heart disorder2MONDO:0005267EFO:0003777
carotid artery disorder2MONDO:0005269EFO:0003781
cardiac arrest2MONDO:0000745EFO:0009492
cerebral atherosclerosis2MONDO:0006694EFO:1000860
acute lung injury2MONDO:0015796EFO:0004610
ovarian cancer2MONDO:0008170MONDO:0008170
acute promyelocytic leukemia2MONDO:0012883EFO:0000224
rectal cancer2MONDO:0006519EFO:1000657
depressive disorder2MONDO:0002050MONDO:0002050
viral infectious disease2MONDO:0005108EFO:0000763
type 2 diabetes mellitus2MONDO:0005148MONDO:0005148
Charcot-Marie-Tooth disease2MONDO:0015626MONDO:0007309
beta thalassemia2MONDO:0019402MONDO:0016486
neuralgia2MONDO:0021667EFO:0005762
lung neoplasm2MONDO:0021117MONDO:0008903
plasma cell neoplasm2MONDO:0004959EFO:0000200
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
atherosclerosis2MONDO:0005311EFO:0003914
vascular disorder2MONDO:0005385EFO:0004264
diabetic neuropathy1MONDO:0006626EFO:1000783
essential thrombocythemia1MONDO:0005029EFO:0000479
acquired polycythemia vera1MONDO:0009891EFO:0002429
primary myelofibrosis1MONDO:0009692EFO:0002430
anaplastic astrocytoma1MONDO:0016684EFO:0002499
anaplastic oligodendroglioma1MONDO:0016696EFO:0002501
temporomandibular joint disorder1MONDO:0005473EFO:0005279
gliosarcoma1MONDO:0016681EFO:1001465
acne1MONDO:0011438EFO:0003894
burn1MONDO:0043519EFO:0009516
soft tissue sarcoma1MONDO:0018078EFO:1001968
autism1MONDO:0005260EFO:0003758
breast neoplasm1MONDO:0021100MONDO:0007254
colonic neoplasm1MONDO:0005401MONDO:0021063
hypertensive disorder1MONDO:0005044EFO:0000537
glioma1MONDO:0021042MONDO:0100342
pulmonary alveolar proteinosis1MONDO:0001437MONDO:0001437
asthma1MONDO:0004979MONDO:0004979
type 1 diabetes mellitus1MONDO:0005147MONDO:0005147
osteoarthritis1MONDO:0005178MONDO:0005178
neoplasm1MONDO:0005070MONDO:0004992
hereditary breast ovarian cancer syndrome1MONDO:0003582Orphanet:145
pancreatic ductal adenocarcinoma1MONDO:0005184MONDO:0005184
basal cell carcinoma0MONDO:0020804EFO:0004193

17 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 399.

Phase distribution

PhaseTrials
Not specified133
PHASE283
PHASE446
PHASE344
PHASE141
PHASE1/PHASE222
PHASE2/PHASE317
EARLY_PHASE113

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07414693PHASE4RECRUITINGEffect of Vitamin C on Length of Hospital Stay in Children With Severe Pneumonia
NCT00140166PHASE4COMPLETEDTreatment of Acute Schizophrenia With Vitamin Therapy
NCT00303160PHASE4UNKNOWNEffect of Helicobacter Pylori on the Availability of Vitamin E and C
NCT00356954PHASE4COMPLETEDNASPI: N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization
NCT00519337PHASE4COMPLETEDImpact of Ascorbic Acid on Post-Cardiothoracic Surgery Inflammation
NCT00869427PHASE4TERMINATEDVitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured
NCT01055418PHASE4COMPLETEDCognitive and Cerebral Blood Flow Effects of Vitamin C
NCT01090895PHASE4UNKNOWNTreatment of Reperfusion Event by Vitamin C Infusion
NCT01167569PHASE4COMPLETEDStudy of High Dose Vitamin C On Outcome in Cardiac Surgery Patients
NCT01322061PHASE4COMPLETEDVitamin C Efficacy in Reducing Post Operative Pain
NCT01332578PHASE4COMPLETEDA Comparison of Solid and Soluble Forms of Cold and Influenza Remedies
NCT01350102PHASE4TERMINATEDThe Relationship of Hemoglobin A1c and Diabetic Wound Healing
NCT01356433PHASE4COMPLETEDInfluence of Oral Vitamin C Supplement on the Inflammation Status in Dialysis Patients
NCT01558622PHASE4UNKNOWNIntraoperative Use of Dexketoprofen Trometamol, Pethidine Hcl, Tramadol Hcl and Their Combinations for Postoperative Pain Management in Laparoscopic Nissen Fundoplication
NCT01595516PHASE4COMPLETEDNebivolol and Endothelial Regulation of Fibrinolysis (NERF)
NCT01743742PHASE4COMPLETEDFirst-day High Dose Vitamin C, E in Severe Birth Asphyxia
NCT01865916PHASE4COMPLETED2L Oral Bi-PegLyte Versus 2L Oral MoviPrep Regimen for Outpatient Colonic Preparation
NCT01926132PHASE4UNKNOWNHigh-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage in Chronic Fatigue Patients: Randomized-controlled Study
NCT02019186PHASE4COMPLETEDEffects of Vitamin C and E on Endothelial Function in Adolescent Diabetes
NCT02209636PHASE4COMPLETEDPhosphate Lowering in CKD Trial
NCT02225886PHASE4UNKNOWNAscorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patients
NCT02355197PHASE4COMPLETEDAntioxidants in Gestational Diabetes
NCT02455180PHASE4COMPLETEDPharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients
NCT02631668PHASE4COMPLETEDthe Efficacy and Safety of Vitamin C for Iron Supplementation in Adult IDA Patients
NCT02639741PHASE4COMPLETEDPreoperative Melatonin or Vitamin C Administration on Postoperative Analgesia
NCT02780505PHASE4COMPLETEDAssessment of the Effect of Vitamin C on Anemia in Patients With Continuous Ambulatory Peritoneal Dialysis
NCT02956057PHASE4COMPLETEDPolyethylene Glycol Versus Low Volume Solutions Prior to Colonoscopy
NCT03049085PHASE4UNKNOWNEffect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting
NCT03228238PHASE4TERMINATEDANti-Oxidant in Variant Angina (ANOVA) Trial
NCT03252418PHASE4COMPLETEDAscorbic Acid Versus Diode Laser in the Treatment of Gingival Hyperpigmentation
NCT03335124PHASE4TERMINATEDThe Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
NCT03581149PHASE4UNKNOWNTolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients
NCT03698474PHASE4COMPLETEDComparison of Different Low Volume Solutions Prior to Colonoscopy
NCT03889158PHASE4TERMINATEDEffect of Age and Fitness on Vascular Function and Oxidative Stress During Acute Inflammation
NCT03921099PHASE4UNKNOWNImpact of Ascorbic Acid in the Prevention of Vancomycin Induced Nephrotoxicty
NCT04135378PHASE4COMPLETEDEffect of Low Doses of Vitamin C on Salivary Cortisol , Heart Rate , Blood Pressure During Group Presentation
NCT04210453PHASE4UNKNOWNThe Impact of Vitamin C on Postoperative Acute Kidney Injury in Risk Patients Undergoing Valvular Heart Surgery
NCT04334967PHASE4SUSPENDEDHydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
NCT04468139PHASE4UNKNOWNThe Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19
NCT04472000PHASE4TERMINATEDCan Vitamin C Reduce the Risk of Postoperative Shoulder Stiffness?

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot